ReviewDiscover oncology2026
Current situation and research progress of luteolin in the treatment of gastrointestinal malignant tumors.
Review in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Luteolin, known for its anti-inflammatory and antioxidant properties, has garnered attention for its potential anticancer effects. Research has shown that luteolin can modulate the proliferation, migration, invasion, drug resistance, and apoptosis of digestive tract cancer cells by targeting specific pathways. This review summarizes the current understanding of luteolin's impact on five types of digestive tract malignancies both in vitro and in vivo, elucidates its molecular mechanisms in regulating these cancers, and highlights the existing limitations and gaps in research. This analysis aims to inform the safety assessment, enhance the bioavailability, and guide the formulation development and clinical utilization of luteolin in the context of digestive tract malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.